Clinical Trial

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2025-09-22; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2025-10-21
Trial Details
NCT Number NCT07199465
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Cytomegalovirus Prophylaxis
Enrollment 40 participants
Start Date 2026-03-30
Primary Completion 2028-04-14 (estimated)
Study Completion 2028-05-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-13